MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-15-2024
Brickell Biotech Operating Cycle 2011-2026 | BBI
Annual Operating Cycle Brickell Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 254 | 135 | 224 | 79.2 | 100 | 217 | - | 38.1 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 254 | 38.1 | 150 |
Quarterly Operating Cycle Brickell Biotech
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.8 | - | - | 1.12 K | 3.42 K | 170 | 398 | 118 | 144 | 137 | 122 | 98.7 | 118 | 75.8 | 78.9 | 60.9 | 82.7 | 99.3 | 80.5 | 79 | 111 | 84.6 | 163 | 133 | 271 | 288 | 195 | 84.7 | 90.3 | 125 | 21 | 148 | 10.7 | 349 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.42 K | 10.7 | 266 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K |  USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aclaris Therapeutics
ACRS
|
6.01 | $ 2.88 | -4.26 % | $ 223 M | USA |
 |
Cellectis S.A.
CLLS
|
136 | $ 4.82 | -0.41 % | $ 116 M |  France |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
408 | $ 10.81 | -4.21 % | $ 699 M | USA |
 |
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
349 | - | -7.31 % | $ 87 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
127 | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
CASI Pharmaceuticals
CASI
|
135 | $ 0.86 | 0.86 % | $ 117 M | USA |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
195 | $ 26.33 | -1.68 % | $ 1.28 B | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Catalyst Biosciences
CBIO
|
410 | $ 11.18 | -5.73 % | $ 736 M | USA |
 |
Anika Therapeutics
ANIK
|
325 | $ 9.41 | -2.08 % | $ 138 M | USA |
 |
Certara
CERT
|
88.6 | $ 8.74 | -0.85 % | $ 1.4 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Axon Enterprise
AXON
|
116 | $ 563.06 | -0.86 % | $ 42.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Celldex Therapeutics
CLDX
|
86.5 | $ 27.12 | -0.15 % | $ 1.75 M | USA |
 |
Aytu BioScience
AYTU
|
360 | $ 2.78 | 6.92 % | $ 17.5 M | USA |
 |
AstraZeneca PLC
AZN
|
206 | $ 91.64 | -0.32 % | $ 96.9 B | Britain |